Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Kintai Therapeutics was a biotechnology company dedicated to pioneering precision enteric medicines by leveraging the body's enteric signaling network. Their research focused on understanding and modulating gut-brain and gut-immune axes to develop novel treatments for diseases in immunology, oncology, and neuroscience. Kintai aimed to create a new class of medicines by targeting the complex interactions within the gut. In November 2022, Kintai Therapeutics was acquired by Senda Biosciences, integrating its platform and talent into Senda's efforts to develop programmable medicines.
Served as the primary center for research and development, discovery science, corporate strategy, and administrative operations.
Located within the vibrant Kendall Square ecosystem, providing proximity to leading academic institutions like MIT and Harvard, other biotech companies, and venture capital firms.
As a Flagship Pioneering-founded biotech, the work culture was likely characterized by scientific rigor, innovation, collaboration, and a fast-paced environment focused on translational research.
The Cambridge location was strategically important for access to top scientific talent, cutting-edge research infrastructure, and a supportive network for biotech growth.
Prior to its acquisition, Kintai Therapeutics' operations were primarily based in the United States, with its headquarters in Cambridge, MA, serving as its main hub for research and development. Any global activities would have likely involved research collaborations or considerations for future clinical trials. Post-acquisition, its legacy and assets are part of Senda Biosciences' broader global strategy.
215 First Street, Suite 210
Cambridge
MA
USA
No additional office locations available.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Kintai Therapeutics' leadership includes:
Kintai Therapeutics has been backed by several prominent investors over the years, including:
Kintai Therapeutics was acquired by Senda Biosciences in November 2022 and no longer operates as an independent entity. Therefore, there have been no executive hires or exits for Kintai Therapeutics in the last 12 months. Key leadership transitions occurred prior to or as part of the acquisition.
Discover the tools Kintai Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Prior to its acquisition, Kintai Therapeutics likely utilized standard corporate email formats based on its domain kintaitx.com. Common formats include first initial followed by last name, or first name followed by last name. These email addresses are no longer active.
[first_initial][last]@kintaitx.com
Format
jdoe@kintaitx.com
Example
0 (Company acquired, emails defunct; historically estimated 75-85)%
Success rate
PR Newswire • November 15, 2022
Senda Biosciences announced it has acquired Kintai Therapeutics. The acquisition combines Kintai's pioneering work in precision enteric medicines and its talented team with Senda's proprietary platform and programs....more
Business Wire • October 8, 2019
Kintai Therapeutics launched, after being founded within Flagship Labs, with a focus on the enteric signaling network and its role in health and disease. The company aimed to develop a new class of medicines for a broad range of diseases....more
FierceBiotech • January 7, 2020
Kintai Therapeutics appointed Paul-Peter Tak, M.D., Ph.D., as its president and CEO. Dr. Tak joined Kintai from GlaxoSmithKline, where he held several senior leadership roles....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Kintai Therapeutics, are just a search away.